Info

Brand Name

Rituxan®

Company

IDEC Pharmaceuticals

Class

• Chimeric/murine monoclonal antibody directed against CD20 expressed on B lymphocytes both normal and malignant

Mechanism of Action

• Antibody and cell mediated lysis of B lymphocytes

Indications

• Primary indications: treatment of CD20 positive B-cell non Hodgkin's Lymphoma

• Chills shortly after infusion

Drug Interactions

• None

Formulation

• 100 mg and 500 mg vials

Dosage

• 375 mg/m2 I.V.

0 0

Post a comment